ABBV-428

N/A

Report date: 2024/10/30 20:00:43

Base Information

Drug NameABBV-428

Drug Alias NameABBV-428ABBV428

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionTumor necrosis factor receptor superfamily member 5 agonistsAnti-Mesothelin

TargetsTumor necrosis factor receptor superfamily member 5Mesothelin

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesTaiwanAustralia +[4]

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesAbbvie Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAbbvie Inc

Active IndicationsN/A

Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A